Publications by authors named "J Abrahamsson"
Article Synopsis
- Several genomic subsets of mutations in acute myeloid leukemia (AML) patients were studied to understand their impact on outcomes and the underlying biology, revealing that type D mutations correlated with poorer survival rates compared to other types.
- In a cohort of over 4,000 patients, a study found that those with type A, B, and rare variants had more favorable overall survival rates, while type D patients exhibited significantly worse outcomes.
- The research highlighted that codon optimality in type D mutations affects gene expression and translation efficiency, leading to poorer prognostic implications and indicating the need for a potential reclassification of type D patients to higher-risk groups.
Characterization of Pediatric Acute Myeloid Leukemia With t(7;12)(q36;p13).
Genes Chromosomes Cancer
November 2024
Article Synopsis
- Acute myeloid leukemia (AML) with the t(7;12) translocation is common in infants and has been recognized by the WHO, although the exact mechanism behind its development is unclear.
- A study of 12 pediatric AML cases with this translocation found no significant difference in survival rates compared to other AML types, but noted a consistent high expression of MNX1 across all cases.
- Whole transcriptome and genome sequencing revealed various fusion transcripts, primarily involving NOM1, but emphasized the importance of MNX1's overexpression as the key driving factor in this AML subtype.
Purpose: Cisplatin-based combination chemotherapy (CHT) is standard of care in metastatic urothelial cancer (mUC); however, no predictive molecular biomarkers are available for clinical use. The aim of this study was to investigate the impact of molecular subtypes in relation to treatment response and survival in patients with mUC treated with first-line CHT.
Patients And Methods: Molecular subtype classification according to the Lund Taxonomy (LundTax) was performed by tumor transcriptomic profiling and immunostaining in a retrospective cohort.
Aim: To study Swedish pediatric oncologists' practical and emotional experiences of referring, including and/or treating children in early-phase clinical trials.
Methods: A nationwide study was conducted using a mixed-method approach. Structured interviews based on a study-specific questionnaire and participants' personal reflections were utilized.